{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:03:35Z","timestamp":1780423415207,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier","isbn-type":[{"value":"9780443431746","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.vh.2026.02.006","type":"book-chapter","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:24:46Z","timestamp":1773087886000},"page":"317-344","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic comorbidities in overt Cushing\u2019s syndrome"],"prefix":"10.1016","author":[{"given":"Laura","family":"Gonz\u00e1lez Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Garc\u00eda Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.vh.2026.02.006_bib0001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1507\/endocrj.K09E-260","article-title":"Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing\u2019s syndrome","volume":"57","author":"Akaza","year":"2010","journal-title":"Endocrine Journal"},{"issue":"06","key":"10.1016\/bs.vh.2026.02.006_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2006-944545","article-title":"Patients with Cushing\u2019s syndrome have increased intimal media thickness at different vascular levels: Comparison with a population matched for similar cardiovascular risk factors","volume":"38","author":"Albiger","year":"2006","journal-title":"Hormone and Metabolic Research"},{"issue":"4","key":"10.1016\/bs.vh.2026.02.006_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11102-005-1172-7","article-title":"Cardiovascular risk in Cushing\u2019s syndrome","volume":"7","author":"Arnaldi","year":"2004","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/bs.vh.2026.02.006_bib0004","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1210\/jc.2012-3547","article-title":"Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing\u2019s syndrome","volume":"98","author":"Barahona","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1016\/bs.vh.2026.02.006_bib0005","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1210\/jc.2009-0766","article-title":"Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing\u2019s syndrome","volume":"94","author":"Barahona","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0006","first-page":"284","article-title":"Diabetes mellitus secondary to Cushing\u2019s disease","volume":"9","author":"Barbot","year":"2018"},{"key":"10.1016\/bs.vh.2026.02.006_bib0007","first-page":"116137","article-title":"Adipose tissue in cortisol excess: What Cushing\u2019s syndrome can teach us?","volume":"223","author":"Bavaresco","year":"2024"},{"issue":"3","key":"10.1016\/bs.vh.2026.02.006_bib0008","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12020-007-0033-8","article-title":"Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing\u2019s Syndrome","volume":"31","author":"Baykan","year":"2007","journal-title":"Endocrine"},{"key":"10.1016\/bs.vh.2026.02.006_bib0009","doi-asserted-by":"crossref","first-page":"1350010","DOI":"10.3389\/fendo.2024.1350010","article-title":"The thrombotic risk in Cushing\u2019s syndrome\u2014questions, answers, and the algorithm to consider in its assessment: Part I\u2014thrombotic risk not related to surgery","volume":"15","author":"Bryk-Wi\u0105zania","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/bs.vh.2026.02.006_bib0010","first-page":"330","article-title":"Thromboembolic disease in hypercortisolism","volume":"28","author":"Capatina","year":"2021"},{"key":"10.1016\/bs.vh.2026.02.006_bib0011","first-page":"e13175","article-title":"Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality","volume":"34","author":"Clayton","year":"2022"},{"issue":"7","key":"10.1016\/bs.vh.2026.02.006_bib0012","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing\u2019s disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study","volume":"4","author":"Clayton","year":"2016","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"8","key":"10.1016\/bs.vh.2026.02.006_bib0013","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0014","first-page":"750","article-title":"Cardiovascular health and mortality in Cushing\u2019s disease","volume":"25","author":"Coulden","year":"2022"},{"issue":"6","key":"10.1016\/bs.vh.2026.02.006_bib0015","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing\u2019s syndrome: A cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000318566","article-title":"Cardiovascular disease in Cushing\u2019s syndrome: Heart versus vasculature","volume":"92","author":"De Leo","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12902-020-00665-7","article-title":"Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): A prospective non-interventional follow-up study","volume":"21","author":"Ehrlich","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"10.1016\/bs.vh.2026.02.006_bib0018","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-012-9764-2","article-title":"Coronary microvascular function in patients with Cushing\u2019s syndrome","volume":"43","author":"Fallo","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/bs.vh.2026.02.006_bib0020","first-page":"746","article-title":"Hypercoagulability in Cushing\u2019s syndrome: Incidence, pathogenesis and need for thromboprophylaxis protocols","volume":"25","author":"Feelders","year":"2022"},{"issue":"2","key":"10.1016\/bs.vh.2026.02.006_bib0021","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s12020-024-03856-7","article-title":"Cardiac magnetic resonance reveals biventricular impairment in Cushing\u2019s syndrome: A multicentre case-control study","volume":"85","author":"Feola","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/bs.vh.2026.02.006_bib0022","first-page":"M133","article-title":"Metabolic comorbidities in Cushing\u2019s syndrome","volume":"173","author":"Ferra\u00f9","year":"2015"},{"key":"10.1016\/bs.vh.2026.02.006_bib0023","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: A guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"6","key":"10.1016\/bs.vh.2026.02.006_bib0024","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: A pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"key":"10.1016\/bs.vh.2026.02.006_bib0026","first-page":"2237","article-title":"Cushing\u2019s syndrome","volume":"402","author":"Gadelha","year":"2023"},{"issue":"7","key":"10.1016\/bs.vh.2026.02.006_bib0027","doi-asserted-by":"crossref","first-page":"e2407","DOI":"10.1210\/clinem\/dgaf094","article-title":"NAFLD vs MASLD (metabolic dysfunction\u2013associated steatotic liver disease)\u2014Why the need for a change of nomenclature?","volume":"110","author":"Gastaldelli","year":"2025","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/bs.vh.2026.02.006_bib0028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-13-0754","article-title":"Is diabetes in Cushing\u2019s syndrome only a consequence of hypercortisolism?","volume":"170","author":"Giordano","year":"2014","journal-title":"European Journal of Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/bs.vh.2026.02.006_bib0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000314294","article-title":"Management of dyslipidemia in Cushing\u2019s syndrome","volume":"92","author":"Greenman","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/bs.vh.2026.02.006_bib0030","first-page":"47","article-title":"Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity","volume":"48","author":"Guarnotta","year":"2025"},{"key":"10.1016\/bs.vh.2026.02.006_bib0031","first-page":"101521","article-title":"Epidemiology and mortality of Cushing\u2019s syndrome","volume":"35","author":"Hakami","year":"2021"},{"issue":"8","key":"10.1016\/bs.vh.2026.02.006_bib0033","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","article-title":"The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality","volume":"107","author":"Limumpornpetch","year":"2022","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1016\/bs.vh.2026.02.006_bib0034","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0735-1097(03)00493-5","article-title":"Left ventricular structural and functional characteristics in Cushing\u2019s syndrome","volume":"41","author":"Lorenza","year":"2003","journal-title":"JACC"},{"issue":"3","key":"10.1016\/bs.vh.2026.02.006_bib0036","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/07853890.2016.1252055","article-title":"Markers of atherosclerosis in patients with Cushing\u2019s syndrome: a meta-analysis of literature studies","volume":"49","author":"Lupoli","year":"2017","journal-title":"Annals of medicine"},{"issue":"6","key":"10.1016\/bs.vh.2026.02.006_bib0035","doi-asserted-by":"crossref","first-page":"e2037","DOI":"10.1210\/clinem\/dgae568","article-title":"Fatty liver disease along Cushing syndrome evolution","volume":"110","author":"Marengo","year":"2025","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/bs.vh.2026.02.006_bib0032","doi-asserted-by":"crossref","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","article-title":"Cardiac structure and function in Cushing\u2019s syndrome: A cardiac magnetic resonance imaging study","volume":"99","author":"Kamenick\u00fd","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1660316","article-title":"Liver impairment and medical management of Cushing syndrome and MACS","volume":"16","author":"Minasyan","year":"2025","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/bs.vh.2026.02.006_bib0038","first-page":"548","article-title":"Cardiac disease in Cushing\u2019s syndrome. Emphasis on the role of cardiovascular magnetic resonance imaging","volume":"83","author":"Moustaki","year":"2024"},{"key":"10.1016\/bs.vh.2026.02.006_bib0039","article-title":"Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000443864","article-title":"Metabolic alterations and cardiovascular outcomes of cortisol excess","volume":"46","author":"Pivonello","year":"2016","journal-title":"Frontiers of Hormone Research"},{"key":"10.1016\/bs.vh.2026.02.006_bib0041","first-page":"327","article-title":"The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome","volume":"34","author":"Pivonello","year":"2005"},{"key":"10.1016\/bs.vh.2026.02.006_bib0042","first-page":"611","article-title":"Complications of Cushing\u2019s syndrome: State of the art","volume":"4","author":"Pivonello","year":"2016"},{"key":"10.1016\/bs.vh.2026.02.006_bib0043","first-page":"e901","article-title":"Long-term consequences of Cushing syndrome: A systematic literature review","volume":"109","author":"Puglisi","year":"2024"},{"issue":"6","key":"10.1016\/bs.vh.2026.02.006_bib0044","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and disease-specific mortality in patients with cushing disease: A Swedish nationwide study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0045","first-page":"170","article-title":"Cushing syndrome: A review","volume":"330","author":"Reincke","year":"2023"},{"issue":"12","key":"10.1016\/bs.vh.2026.02.006_bib0046","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1210\/jc.2009-1588","article-title":"Hypertrophic remodeling of subcutaneous small resistance arteries in patients with Cushing\u2019s syndrome","volume":"94","author":"Rizzoni","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2026.02.006_bib0047","first-page":"e13143","article-title":"Glucose and lipid metabolism abnormalities in Cushing\u2019s syndrome","volume":"34","author":"Salehidoost","year":"2022"},{"key":"10.1016\/bs.vh.2026.02.006_bib0048","first-page":"189","article-title":"Glucose metabolism abnormalities in cushing syndrome: From molecular basis to clinical management","volume":"38","author":"Scaroni","year":"2017"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0049","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","article-title":"Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission","volume":"64","author":"Schernthaner-Reiter","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/bs.vh.2026.02.006_bib0050","first-page":"188","article-title":"Comorbidities in Cushing\u2019s disease","volume":"18","author":"Sharma","year":"2015"},{"key":"10.1016\/bs.vh.2026.02.006_bib0051","first-page":"6735","article-title":"Pathogenesis of hepatic steatosis: The link between hypercortisolism and non-alcoholic fatty liver disease","volume":"19","author":"Tarantino","year":"2013"},{"issue":"4","key":"10.1016\/bs.vh.2026.02.006_bib0052","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"van der Pas","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0053","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-022-02320-x","article-title":"Current clinical practice for thromboprophylaxis management in patients with Cushing\u2019s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)","volume":"17","author":"van Haalen","year":"2022","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/bs.vh.2026.02.006_bib0054","doi-asserted-by":"crossref","unstructured":"Varlamov E. V., Langlois F., Vila G., Fleseriu M. Invited Review Cardiovascular risk assessment, thromboembolism and infection prevention in Cushing\u2019s syndrome-a practical approach. 184(5):R207-R224; 2019.","DOI":"10.1530\/EJE-20-1309"},{"issue":"2","key":"10.1016\/bs.vh.2026.02.006_bib0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1016\/bs.vh.2026.02.006_bib0056","doi-asserted-by":"crossref","first-page":"bvaf008","DOI":"10.1210\/jendso\/bvaf008","article-title":"Relationship among fragility fractures and the overall cardiovascular burden in endogenous Cushing syndrome","volume":"9","author":"Voltan","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/bs.vh.2026.02.006_bib0057","first-page":"805","article-title":"Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing\u2019s syndrome: A systematic meta-analysis","volume":"9","author":"Wagner","year":"2018"},{"key":"10.1016\/bs.vh.2026.02.006_bib0058","first-page":"299","article-title":"Morbidity of Cushing\u2019s syndrome and impact of treatment","volume":"47","author":"Webb","year":"2018"},{"issue":"12","key":"10.1016\/bs.vh.2026.02.006_bib0059","first-page":"3505","article-title":"Epicardial and pericardial adiposity without myocardial steatosis in Cushing syndrome","volume":"106","author":"Wolf","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2026.02.006_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-11-0601","article-title":"Increased myocardial fibrosis and left ventricular dysfunction in Cushing\u2019s syndrome","volume":"166","author":"Yiu","year":"2012","journal-title":"European Journal of Endocrinology"}],"container-title":["Vitamins and Hormones","Hypercortisolism: Diagnosis and Differential Diagnosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672926000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672926000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:29:10Z","timestamp":1780421350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672926000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443431746"],"references-count":60,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2026.02.006","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}